BL
MCID: BRK010
MIFTS: 68

Burkitt Lymphoma (BL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Burkitt Lymphoma

MalaCards integrated aliases for Burkitt Lymphoma:

Name: Burkitt Lymphoma 57 12 53 59 74 37 29 13 55 6 44 15 38 38 40 72 33
Burkitt's Lymphoma 12 75 53 15
Bl 57 53 74
Small Non-Cleaved Cell Lymphoma, Burkitt's Type 12
Malignant Lymphoma, Burkitt's Type 12
Small Non-Cleaved Cell Lymphoma 59
Lymphoma, Small Noncleaved-Cell 72
Burkitt's Tumor or Lymphoma 12
Burkitt Lymphoma/leukaemia 12
Burkitt Lymphoma, Somatic 57
Burkitts Lymphoma 17
Burkitt's Tumor 12
Burkitt Tumor 74

Characteristics:

Orphanet epidemiological data:

59
burkitt lymphoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-5/10000 (Africa),1-9/1000000 (United States); Age of onset: All ages; Age of death: any age;

OMIM:

57
Inheritance:
somatic mutation
isolated cases

Miscellaneous:
accounts for 30-50% of lymphomas in children
accounts for 1-2% of lymphomas in adults
three distinct clinical forms - endemic (equatorial africa), sporadic, and immunodeficiency-associated (e.g., hiv infection)


HPO:

32
burkitt lymphoma:
Inheritance somatic mutation sporadic


Classifications:



External Ids:

Disease Ontology 12 DOID:8584
OMIM 57 113970
KEGG 37 H00008
ICD9CM 35 200.2
MeSH 44 D002051
NCIt 50 C2912 C7400
SNOMED-CT 68 22197008 77381001
ICD10 33 C83.7 C83.70
MESH via Orphanet 45 D002051 D008228
ICD10 via Orphanet 34 C83.7
UMLS via Orphanet 73 C0006413 C0079770
Orphanet 59 ORPHA543
MedGen 42 C0006413
UMLS 72 C0006413 C0079770

Summaries for Burkitt Lymphoma

NIH Rare Diseases : 53 Burkitt lymphoma (BL) is a very fast-growing type of cancer. It is a form of B-cell non-Hodgkin's lymphoma. There are 3 recognized forms of BL: Endemic (African) - the most common form, found mainly in central Africa, where it is associated with the Epstein Barr virus (EBV). It is most common in children. This form often manifests as enlargement of the jaw or facial bones. Sporadic - a rarer form, seen in all parts of the world, that often develops in the abdomen with bone marrow involvement. The kidneys, ovaries, breasts or other organs may also be involved. This form commonly affects children and young adults. Immunodeficiency-associated - occurs primarily in people with HIV infection, and less commonly in people with other immunodeficiency disorders or recipients of organ transplants. Signs and symptoms may differ depending on the form of BL and the organs or body systems involved. When it spreads, weakness and fatigue often develop. Lymphoma cells may build up in the lymph nodes and other organs, causing swelling. Central nervous system involvement is possible with all forms of BL, particularly when there is advanced-stage disease. The exact cause of BL is not known. EBV infection appears to play a role in virtually all cases of endemic (African) BL, and a minority of sporadic and immunodeficiency-associated BL. While acquired (not inherited) genetic changes involving the MYC gene and other genes are present within BL cancer cells, it is unclear what causes these genetic changes to occur. Without timely treatment, BL is rapidly fatal. Treatment involves intensive chemotherapy, which includes chemotherapy to the fluid surrounding the brain and spinal cord. The majority of people treated with aggressive therapy achieve long-term remission.

MalaCards based summary : Burkitt Lymphoma, also known as burkitt's lymphoma, is related to lymphoma and lymphoma, hodgkin, classic. An important gene associated with Burkitt Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Viral carcinogenesis and Epstein-Barr virus infection. The drugs Vindesine and Tenofovir have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are hyperuricemia and increased lactate dehydrogenase activity

Disease Ontology : 12 A mature B-cell neoplasm of B-cells found in the germinal center.

OMIM : 57 Burkitt lymphoma is a rare, aggressive B-cell lymphoma that accounts for 30 to 50% of lymphomas in children but only 1 to 2% of lymphomas in adults (Harris and Horning, 2006). It results from chromosomal translocations that involve the MYC gene (190080) and either the lambda or the kappa light chain immunoglobulin genes (147220, 147200). Burkitt lymphoma is causally related to the Epstein-Barr virus (EBV), although the pathogenetic mechanisms are not clear. (113970)

KEGG : 37
Burkitt lymphoma (BL) is a highly aggressive mature B-cell non-Hodgkin's lymphoma consisting of endemic, sporadic, and immunodeficiency-associated variants. Endemic BL (eBL) affects children and young adults in Africa and some other geographical areas and carries Epstein-Barr virus (EBV) in more than 95% of cases. In contrast, sporadic BL (sBL) among adolescents in Europe and North America are mostly EBV-negative. A third type of BL is associated with HIV-infection in adults. All of these subtypes possess chromosomal rearrangements of the c-myc oncogene, the genetic hallmark of BL that contributes to lymphomagenesis through alterations in cell cycle regulation, cellular differentiation, apoptosis, cellular adhesion, and metabolism. Many BL carry point mutation in the p53 tumor suppressor gene or other defects in the p14ARF-MDM2-p53 pathway, and inactivation of the p16INK4a gene by promoter methylation or homozygous deletion. This indicates that disruption of both the pRb and p53 tumor suppressor pathways is critical for BL development.

UniProtKB/Swiss-Prot : 74 Burkitt lymphoma: A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass.

Wikipedia : 75 Burkitt lymphoma is a cancer of the lymphatic system, particularly B lymphocytes found in the germinal... more...

Related Diseases for Burkitt Lymphoma

Diseases related to Burkitt Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 611)
# Related Disease Score Top Affiliating Genes
1 lymphoma 32.9 TCL1A SH2D1A PVT1 MYC CXCR5 BCL6
2 lymphoma, hodgkin, classic 32.5 PVT1 MIR155 BCL6
3 lymphoma, non-hodgkin, familial 32.3 TCL1A SH2D1A MYC CXCR5 BCL6 BAX
4 diffuse large b-cell lymphoma 32.0 MYC MIR155 MIR145 MIR143 MIR127 BCL6
5 follicular lymphoma 31.8 MYC MIR155 BCL6 AICDA
6 leukemia, chronic lymphocytic 31.6 TCL1A CXCR5 BCL6 BAX AICDA
7 mature b-cell neoplasm 31.6 SH2D1A PVT1 MYC BCL6
8 precursor t-cell acute lymphoblastic leukemia 31.2 TCL1A MYC BAX
9 primary effusion lymphoma 31.2 TCL1A MYC BCL6
10 lymphoma, mucosa-associated lymphoid type 31.1 CXCR5 CXCL13 BCL6
11 intestinal disease 31.0 PMS2 MYC BCL6
12 composite lymphoma 31.0 SOX11 BCL6
13 hematologic cancer 31.0 PVT1 MYC BCL6 BAX
14 acquired immunodeficiency syndrome 31.0 NEAT1 MYC BCL6
15 mantle cell lymphoma 30.9 SOX11 MYC BCL6
16 bladder cancer 30.8 PVT1 MYC MIR145 MIR143 MIR127
17 nasopharyngeal carcinoma 30.0 PVT1 NEAT1 MYC MIR34B
18 acute promyelocytic leukemia 29.1 PVT1 NEAT1 MYC MIRLET7C BAX
19 pancreatic cancer 29.0 PVT1 NEAT1 MIR34B MIR155 MIR143 MIR127
20 leukemia, acute myeloid 28.7 MYC MIRLET7C MIR34B MIR155
21 breast cancer 28.2 TP53COR1 PVT1 NEAT1 MYC MIR155 MIR145
22 ovarian cancer 27.6 PVT1 NEAT1 MYC MIRLET7C MIR34B MIR155
23 colorectal cancer 27.6 TP53COR1 PVT1 PMS2 NEAT1 MYC MIR34B
24 hepatocellular carcinoma 27.6 TP53COR1 PVT1 NEAT1 MYC MIRLET7C MIR155
25 bare lymphocyte syndrome, type i 12.3
26 bare lymphocyte syndrome, type ii 12.3
27 leukemia, acute lymphoblastic 3 11.8
28 childhood ovarian cancer 11.4
29 blind loop syndrome 11.4
30 hypothyroidism, thyroidal or athyroidal, with spiky hair and cleft palate 11.2
31 blepharitis 11.2
32 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 11.0 MYC BCL6
33 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 11.0 CXCR5 BCL6
34 leukocyte disease 10.9 MYC BCL6 BAX
35 b-cell lymphoma 10.9
36 lymphatic system cancer 10.9 SH2D1A MYC BCL6
37 autoimmune lymphoproliferative syndrome, type v 10.9 TCL1A SH2D1A BCL6
38 peripheral t-cell lymphoma 10.9 TCL1A CXCL13 BCL6
39 primary mediastinal large b-cell lymphoma 10.8 MYC BCL6
40 neurosyphilis 10.8 CXCR5 CXCL13
41 diversion colitis 10.7 CXCR5 CXCL13
42 polymyositis 10.7 MIR155 MIR127
43 schuurs-hoeijmakers syndrome 10.7 TCL1A AICDA
44 pancreatic ductal adenocarcinoma 10.6 PVT1 MIR155 MIR145 MIR143
45 ovarian serous carcinoma 10.6 MIR145 MIR143
46 lymphocytic leukemia 10.6
47 intraocular lymphoma 10.5 CXCR5 BCL6
48 cardiac arrest 10.5
49 leprosy 3 10.5
50 hansen's disease 10.5

Graphical network of the top 20 diseases related to Burkitt Lymphoma:



Diseases related to Burkitt Lymphoma

Symptoms & Phenotypes for Burkitt Lymphoma

Human phenotypes related to Burkitt Lymphoma:

59 32 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperuricemia 59 32 frequent (33%) Frequent (79-30%) HP:0002149
2 increased lactate dehydrogenase activity 59 32 frequent (33%) Frequent (79-30%) HP:0025435
3 abnormality of bone marrow cell morphology 59 32 frequent (33%) Frequent (79-30%) HP:0005561
4 neoplasm of the oral cavity 59 32 frequent (33%) Frequent (79-30%) HP:0100649
5 nausea and vomiting 59 32 occasional (7.5%) Occasional (29-5%) HP:0002017
6 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
7 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
8 abnormality of the ovary 59 32 occasional (7.5%) Occasional (29-5%) HP:0000137
9 intestinal obstruction 59 32 occasional (7.5%) Occasional (29-5%) HP:0005214
10 abnormality of the pancreas 59 32 occasional (7.5%) Occasional (29-5%) HP:0001732
11 abnormality of the spleen 59 32 occasional (7.5%) Occasional (29-5%) HP:0001743
12 decreased proportion of cd4-positive t cells 59 32 occasional (7.5%) Occasional (29-5%) HP:0005407
13 abnormality of the liver 59 32 occasional (7.5%) Occasional (29-5%) HP:0001392
14 abnormality of the lymph nodes 59 32 occasional (7.5%) Occasional (29-5%) HP:0002733
15 immunodeficiency 32 HP:0002721
16 burkitt lymphoma 32 HP:0030080

Symptoms via clinical synopsis from OMIM:

57
Neoplasia:
burkitt lymphoma (b-cell lymphoma)
jaw and kidney tumor (endemic form)
ileal, cecal, ovarian, and breast tumors, occasionally (endemic form)
abdominal tumors (immunodeficiency-associated form)
monomorphic cells, medium-sized, with round nuclei, multiple nucleoli, and moderate amount of cytoplasm
more
Laboratory Abnormalities:
elevated lactate dehydrogenase
elevated uric acid
chromosomal translocations involving c-myc (, 8q24) and the immunoglobin lambda light chain (, 22q11.2) locus
chromosomal translocations involving c-myc (, 8q24) and the immunoglobin kappa light chain (, 2p12) locus
chromosomal translocations involving c-myc (, 8q24) and the immunoglobin heavy chain (, 14q32) locus

Clinical features from OMIM:

113970

Drugs & Therapeutics for Burkitt Lymphoma

Drugs for Burkitt Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 448)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
2
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
3
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
4
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
5
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
6 Orange Approved Phase 3
7
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
8
rituximab Approved Phase 3 174722-31-7 10201696
9
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
10
Etoposide Approved Phase 3 33419-42-0 36462
11
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
12
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
13
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
14
Lenograstim Approved, Investigational Phase 3 135968-09-1
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
17
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
18
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
19
Dalteparin Approved Phase 3 9005-49-6
20
Acyclovir Approved Phase 3 59277-89-3 2022
21
Ofloxacin Approved Phase 3 82419-36-1 4583
22
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
23
Gemcitabine Approved Phase 3 95058-81-4 60750
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
25
Tazobactam Approved Phase 3 89786-04-9 123630
26
Piperacillin Approved Phase 3 66258-76-2 43672
27
Vancomycin Approved Phase 3 1404-90-6 441141 14969
28
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
29
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
30
Ribavirin Approved Phase 3 36791-04-5 37542
31
Palivizumab Approved, Investigational Phase 3 188039-54-5
32
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
33
Captopril Approved Phase 3 62571-86-2 44093
34
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
35
Mercaptopurine Approved Phase 3 50-44-2 667490
36
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
37
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
38
Morphine Approved, Investigational Phase 3 57-27-2 5288826
39
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
40
Pegaspargase Approved, Investigational Phase 3 130167-69-0
41
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
42
Ichthammol Approved Phase 3 8029-68-3
43
Blinatumomab Approved, Investigational Phase 3 853426-35-4
44
Thioguanine Approved Phase 3 154-42-7 2723601
45
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
46
tannic acid Approved Phase 3 1401-55-4
47
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
48
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
49
leucovorin Approved Phase 3 58-05-9 143 6006
50
Ifosfamide Approved Phase 3 3778-73-2 3690

Interventional clinical trials:

(show top 50) (show all 692)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
2 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
3 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
4 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
5 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
6 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
7 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
8 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
9 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
10 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
11 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
12 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
13 FAB LMB 96 -- Treatment of Mature B-CELL Lymphoma/Leukemia: A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study Completed NCT00002757 Phase 3 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;methotrexate;prednisolone;prednisone;therapeutic hydrocortisone;vincristine sulfate
14 A RANDOMIZED PROSPECTIVE TRIAL OF CHOP VERSUS MCOP IN ELDERLY PATIENTS WITH INTERMEDIATE AND HIGH GRADE NON-HODGKIN'S LYMPHOMA (AGED 65 YEARS AND OVER) Completed NCT00002576 Phase 3 cyclophosphamide;doxorubicin hydrochloride;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
15 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
16 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
17 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
18 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
19 Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study] Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
20 A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All Completed NCT00005977 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
21 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
22 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
23 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
24 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
25 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
26 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
27 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
28 SWOG-9704 A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant) for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups Completed NCT00004031 Phase 3 CHOP regimen;carmustine;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
29 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
30 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
31 Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
32 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
33 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
34 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
35 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
36 Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas Completed NCT00554164 Phase 3 (R-)CHOP protocol;B-ALL protocol;(R-)CHOP protocol;(R-)CHOP protocol
37 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
38 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
39 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
40 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
41 A Phase III Study of Involved Field Radiation Therapy (IFRT) in Patients With Histologically Aggressive Non-Hodgkin's Lymphoma Following High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) Completed NCT00031668 Phase 3
42 Randomized Trial of Autologous GVHD for Refractory Lymphoma Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine
43 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
44 Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer Completed NCT00369564 Phase 3 glutamic acid
45 Randomized Trial of CHOP Chemotherapy With or Without Rituximab (Chimeric Anti-CD20 Antibody) for HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003595 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
46 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
47 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
48 A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell Transplant And Followed By Maintenance Rituximab Versus Observation Completed NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
49 Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies Completed NCT00381680 Phase 3 vincristine sulfate;prednisone;doxorubicin hydrochloride;pegaspargase;cytarabine;methotrexate;dexamethasone;etoposide;cyclophosphamide;leucovorin calcium;asparaginase;mercaptopurine
50 CART-19 Cells For Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Recruiting NCT03391739 Phase 2, Phase 3

Search NIH Clinical Center for Burkitt Lymphoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cyclophosphamide
Cyclophosphamide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Burkitt Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: burkitt lymphoma

Genetic Tests for Burkitt Lymphoma

Genetic tests related to Burkitt Lymphoma:

# Genetic test Affiliating Genes
1 Burkitt Lymphoma 29 MYC

Anatomical Context for Burkitt Lymphoma

MalaCards organs/tissues related to Burkitt Lymphoma:

41
B Cells, Bone, T Cells, Bone Marrow, Breast, Ovary, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Burkitt Lymphoma:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Burkitt Lymphoma

Articles related to Burkitt Lymphoma:

(show top 50) (show all 8106)
# Title Authors PMID Year
1
Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. 38 8 71
8220424 1993
2
The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition. 38 8
28562582 2017
3
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. 38 8
23143595 2012
4
The genetic landscape of mutations in Burkitt lymphoma. 38 8
23143597 2012
5
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. 38 8
22885699 2012
6
MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. 9 38 88
18802929 2008
7
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. 38 8
16760442 2006
8
Molecular diagnosis of Burkitt's lymphoma. 38 8
16760443 2006
9
Burkitt's lymphoma--the message from microarrays. 38 8
16760450 2006
10
Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. 38 8
12219084 2002
11
Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. 38 8
11118209 2000
12
Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. 38 8
10559294 1999
13
Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. 38 8
9765461 1998
14
Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. 38 8
2833750 1988
15
The t(8;14) chromosome translocation of the Burkitt lymphoma cell line Daudi occurred during immunoglobulin gene rearrangement and involved the heavy chain diversity region. 38 8
3116544 1987
16
Familial Burkitt's lymphoma. Association with altered lymphocyte subsets in family members. 38 8
3487979 1986
17
Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. 38 8
3458257 1986
18
In situ hybridization and translocation breakpoint mapping. I. Nonidentical 22q11 breakpoints for the t(9;22) of CML and the t(8;22) of Burkitt lymphoma. 38 8
6467987 1984
19
The discovery of Burkitt's lymphoma. 38 8
6299496 1983
20
Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma. 38 8
6806672 1982
21
Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. 38 8
946170 1976
22
Update on Burkitt Lymphoma. 38 6
27888884 2016
23
B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. 38 88
19530237 2010
24
Downregulation of microRNAs-143 and -145 in B-cell malignancies. 38 88
17892514 2007
25
Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. 38 88
17173072 2007
26
Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. 38 88
16235244 2006
27
High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. 38 88
14695998 2004
28
Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. 8
6300885 1983
29
Molecular cloning of translocations involving chromosome 15 and the immunoglobulin C alpha gene from chromosome 12 in two murine plasmacytomas. 8
6960358 1982
30
Human immunoglobulin heavy chain genes map to a region of translocations in malignant B lymphocytes. 8
6801764 1982
31
The role of gene dosage and genetic transpositions in carcinogenesis. 8
7312030 1981
32
A sarcoma involving the jaws in African children. 8
13628987 1958
33
Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach. 9 38
19844983 2010
34
Using an automated cell counter to simplify gene expression studies: siRNA knockdown of IL-4 dependent gene expression in Namalwa cells. 9 38
20393449 2010
35
c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma. 9 38
19881537 2010
36
Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. 9 38
20081364 2010
37
Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. 9 38
20023257 2010
38
To the genesis of Burkitt lymphoma: regulation of apoptosis by EBNA-1 and SAP may determine the fate of Ig-myc translocation carrying B lymphocytes. 9 38
19874894 2009
39
Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda. 9 38
20003543 2009
40
[Immunohistochemical study using T-cell lymphoma antibody 1 and CD44 in diagnosis of Burkitt's lymphoma]. 9 38
20079013 2009
41
Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. 9 38
19880779 2009
42
Speckled-like pattern in the germinal center (SLIP-GC), a nuclear GTPase expressed in activation-induced deaminase-expressing lymphomas and germinal center B cells. 9 38
19734146 2009
43
PNAEmu can significantly reduce Burkitt's lymphoma tumor burden in a SCID mice model: cells dissemination similar to the human disease. 9 38
19363465 2009
44
Insights into apoptosis mechanisms induced by DNA-damaging agents in Burkitt's lymphoma cells. 9 38
19557576 2009
45
Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells. 9 38
19421231 2009
46
Activation of mTORC1 signaling pathway in AIDS-related lymphomas. 9 38
19608873 2009
47
[Preclinical study of apoptosis of B-NHL cell lines induced by anti-CD20 monoclonal antibody]. 9 38
19698222 2009
48
Downregulation of RUNX1 by RUNX3 requires the RUNX3 VWRPY sequence and is essential for Epstein-Barr virus-driven B-cell proliferation. 9 38
19403666 2009
49
miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. 9 38
19349957 2009
50
BimL upregulation induced by BCR cross-linking in BL41 Burkitt's lymphoma results from a splicing mechanism of the BimEL mRNA. 9 38
19332026 2009

Variations for Burkitt Lymphoma

ClinVar genetic disease variations for Burkitt Lymphoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MYC NM_002467.6(MYC): c.162G> C (p.Glu54Asp) single nucleotide variant Pathogenic rs121918684 8:128750625-128750625 8:127738379-127738379
2 MYC NM_002467.6(MYC): c.220C> G (p.Pro74Ala) single nucleotide variant Pathogenic rs121918685 8:128750683-128750683 8:127738437-127738437
3 PMS2 NM_000535.7(PMS2): c.1831dup (p.Ile611fs) duplication Pathogenic rs63750250 7:6026565-6026565 7:5986934-5986934
4 PMS2 NM_000535.7(PMS2): c.736_741delinsTGTGTGTGAAG (p.Pro246_Pro247delinsCysValTer) indel Pathogenic rs267608150 7:6037019-6037024 7:5997388-5997393
5 MYC NM_002467.6(MYC): c.214C> T (p.Pro72Ser) single nucleotide variant Pathogenic rs28933407 8:128750677-128750677 8:127738431-127738431
6 MYC NM_002467.6(MYC): c.302A> C (p.Asn101Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121918683 8:128750765-128750765 8:127738519-127738519

Cosmic variations for Burkitt Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5702591 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3
2 COSM28746 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 2:208248388-208248388 3
3 COSM28747 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 2:208248389-208248389 3
4 COSM28748 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 2:208248389-208248389 3
5 COSM28749 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 2:208248389-208248389 3
6 COSM28750 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 2:208248388-208248388 3
7 COSM5702574 FOXO3 central nervous system,brain,other,neoplasm c.583A>T p.K195* 6:108561791-108561791 3
8 COSM5702592 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 3

Copy number variations for Burkitt Lymphoma from CNVD:

7 (show top 50) (show all 157)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13309 1 150547027 150552214 Copy number MCL1 Burkitt''s lymphoma
2 22188 1 166155454 171863618 Gain FASLG Burkitt''s lymphoma
3 25990 1 195253751 195672280 Gain PTPRC Burkitt''s lymphoma
4 26526 1 200970000 201360000 Gain LRRN5 Burkitt''s lymphoma
5 26527 1 200970000 201360000 Gain MDM4 Burkitt''s lymphoma
6 26528 1 200970000 201360000 Gain PIK3C2B Burkitt''s lymphoma
7 26529 1 200970000 201360000 Gain PLEKHA6 Burkitt''s lymphoma
8 26530 1 200970000 201360000 Gain PPP1R15B Burkitt''s lymphoma
9 29698 1 23457835 23714048 Loss E2F2 Burkitt''s lymphoma
10 30116 1 240240000 241350000 Gain ADSS Burkitt''s lymphoma
11 30117 1 240240000 241350000 Gain AKT3 Burkitt''s lymphoma
12 30118 1 240240000 241350000 Gain C1orf100 Burkitt''s lymphoma
13 30119 1 240240000 241350000 Gain C1orf101 Burkitt''s lymphoma
14 30120 1 240240000 241350000 Gain C1orf121 Burkitt''s lymphoma
15 30121 1 240240000 241350000 Gain FAM36A Burkitt''s lymphoma
16 30122 1 240240000 241350000 Gain HNRPU Burkitt''s lymphoma
17 30123 1 240240000 241350000 Gain LOC440742 Burkitt''s lymphoma
18 30124 1 240240000 241350000 Gain ZNF238 Burkitt''s lymphoma
19 42609 10 36983732 37133784 Loss Burkitt''s lymphoma
20 48364 11 1 32410000 Loss FANCF Burkitt''s lymphoma
21 48365 11 1 32410000 Loss PLEKHA7 Burkitt''s lymphoma
22 49723 11 110620000 110810000 Gain C11orf53 Burkitt''s lymphoma
23 49724 11 110620000 110810000 Gain POU2AF1 Burkitt''s lymphoma
24 50222 11 115828212 118580638 Gain Burkitt''s lymphoma
25 50968 11 120700000 134452384 Deletion Burkitt''s lymphoma
26 51055 11 122263650 134452384 Loss Burkitt''s lymphoma
27 51545 11 127825348 127931093 Gain ETS1 Burkitt''s lymphoma
28 67044 12 35400000 132349534 Insertion Burkitt''s lymphoma
29 74099 13 100500000 109100000 Insertion Burkitt''s lymphoma
30 74289 13 103640000 112610000 Loss ANKRD10 Burkitt''s lymphoma
31 74290 13 103640000 112610000 Loss ARHGEF7 Burkitt''s lymphoma
32 74291 13 103640000 112610000 Loss COL4A1 Burkitt''s lymphoma
33 74292 13 103640000 112610000 Loss COL4A2 Burkitt''s lymphoma
34 74293 13 103640000 112610000 Loss EFNB2 Burkitt''s lymphoma
35 74294 13 103640000 112610000 Loss ERCC5 Burkitt''s lymphoma
36 74295 13 103640000 112610000 Loss FGF14 Burkitt''s lymphoma
37 74296 13 103640000 112610000 Loss ING1 Burkitt''s lymphoma
38 74297 13 103640000 112610000 Loss IRS2 Burkitt''s lymphoma
39 74298 13 103640000 112610000 Loss LIG4 Burkitt''s lymphoma
40 74299 13 103640000 112610000 Loss PCCA Burkitt''s lymphoma
41 74300 13 103640000 112610000 Loss RAB20 Burkitt''s lymphoma
42 74301 13 103640000 112610000 Loss SLC10A2 Burkitt''s lymphoma
43 74302 13 103640000 112610000 Loss TNFSF13B Burkitt''s lymphoma
44 75138 13 16000000 114142980 Deletion Burkitt''s lymphoma
45 75160 13 16000000 39500000 Insertion ABCC4 Burkitt''s lymphoma
46 77034 13 39500000 52200000 Deletion Burkitt''s lymphoma
47 79790 13 77800000 100500000 Insertion TBC1D4 Burkitt''s lymphoma
48 80310 13 89580000 96810000 Amplification ABCC4 Burkitt''s lymphoma
49 80311 13 89580000 96810000 Amplification CLDN10 Burkitt''s lymphoma
50 80312 13 89580000 96810000 Amplification DCT Burkitt''s lymphoma

Expression for Burkitt Lymphoma

Search GEO for disease gene expression data for Burkitt Lymphoma.

Pathways for Burkitt Lymphoma

Pathways related to Burkitt Lymphoma according to KEGG:

37
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203
2 Epstein-Barr virus infection hsa05169

GO Terms for Burkitt Lymphoma

Biological processes related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 leukocyte chemotaxis GO:0030595 9.55 CXCR5 CXCL13
2 regulation of smooth muscle contraction GO:0006940 9.54 MIR145 MIR143
3 somatic hypermutation of immunoglobulin genes GO:0016446 9.52 PMS2 AICDA
4 positive regulation of protein oligomerization GO:0032461 9.51 TCL1A BAX
5 negative regulation of glucose import GO:0046325 9.49 MYC MIR143
6 positive regulation of connective tissue replacement GO:1905205 9.48 MIR34B MIR155
7 hypothalamus development GO:0021854 9.46 MYC BAX
8 positive regulation of mitochondrial membrane potential GO:0010918 9.43 TCL1A MYC
9 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.4 MIR34B MIR155
10 angiotensin-activated signaling pathway GO:0038166 9.37 MIR145 MIR143